Leash Bio
United States
- Salt Lake City, UT
- 09/04/2024
- Seed
- $9,300,000
Every single machine learning (ML)-driven breakthrough, from language translation to Go championships, was immediately preceded not by an algorithmic innovation but by a massive, well-controlled, purpose-built dataset. An ML-driven breakthrough in medicinal chemistry is going to require a similar dataset, but such high-quality, well-structured experimental data doesn’t exist yet. We're building that data set by making physical measurements of lots of targets (with automated in-house protein production) screened against lots of compounds (with DNA-encoded chemical libraries). We're also building the ML models, that will eventually be generalizable across any protein and novel medicines using insights from our models.
- Industry Biotechnology Research
- Website https://www.leash.bio/
- LinkedIn https://www.linkedin.com/company/leash-bio/
Related People
Ian Quigley, PhDCo Founder
United States -
Salt Lake City Metropolitan Area
I build biological, chemical, and data systems to address major biomedical problems.
My team and I made 12.7 billion queryable measurements in my basement in 2023.
Mecka | $60,000,000 | (Jun 3, 2026)
Novellia | $18,000,000 | (Jun 3, 2026)
Plot | $10,000,000 | (Jun 3, 2026)
KOSMOS | $5,000,000 | (Jun 3, 2026)
Phosio Corporation | $4,000,000 | (Jun 3, 2026)
StratusGrid | $3,000,000 | (Jun 3, 2026)
Subtle Medical | $33,000,000 | (Jun 3, 2026)
Tavo Biotherapeutics | $17,000,000 | (Jun 3, 2026)
Contraline | $92,500,000 | (Jun 3, 2026)
Gigaton | $26,000,000 | (Jun 3, 2026)
Westmag | $11,000,000 | (Jun 3, 2026)
Inherent | $50,000,000 | (Jun 2, 2026)